Background: Esthesioneuroblastoma (ENB) is a rare neuroendocrine tumor. The
Treatment for this tumor typically consists of surgery followed by multimodality adjuvant therapy, either radiation or chemoradiation.
Although this treatment algorithm is frequently promoted as the standard of care in the literature, physicians often deviate from it.
With no randomized controlled trials and little data on the influence of patient-related factors on outcomes, there continues to be variation in the sequence and utilization of these modalities-surgery, radiation, and chemotherapy-for ENB.
Recent studies have attempted to clarify these issues using national cancer registries.
Jethanamest et al
2 examined staging and treatment data for ENB using the Surveillance, Epidemiology, and End Results Program.
Konuthula et al, 6 on the other hand, examined the prognostic utility of the Kadish staging system using the National Cancer Database (NCDB). To date, no study has performed comparisons between staging systems.
The current paper utilizes the National Cancer Database (NCDB)
to assess factors predictive of primary surgical approach as well as survival. Additionally, it evaluates the prognostic utility of the Kadish staging system, the traditional TNM classification, and the modified TNM-Dulguerov classification. Lastly, we assessed factors associated with positive margin status.
| MATERIALS AND METHODS

| Data source
The data source for this paper was the NCDB, a joint program of the Commission on Cancer (CoC) and the American College of Surgeons, which collects hospital-based registry data for patients with invasive cancer diagnoses from over 1400 CoC-accredited facilities. 7, 8 The data were used in accordance with the NCDB Participant User Files.
This study received an Institutional Review Board Waiver by Memorial Sloan Kettering Cancer Center.
| Study cohort
We identified patients with a diagnosis of ENB from 2004 to 2015 who were 18 years of age or older. We filtered the database for the following histologic diagnoses based on the International Classification of Diseases for Oncology, third edition (ICDO-3): olfactory neurogenic tumor (9520), olfactory neurocytoma (9521), olfactory neuroblastoma (9522), and olfactory neuroepithelioma (9523). 9 We included only patients with histologically confirmed diagnoses and those with malignant tumors (ie, invasion past basement membrane). We Causing bone erosion or destruction, including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates T3
Invades any of the following: bone of the posterior wall of the maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses T4a
Invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid, or frontal sinuses T4b
Invades any of the following: orbital apex, dura mater, brain, middle cranial fossa, cranial nerves other than V2, nasopharynx, or clivus 10, 11 We also excluded patients for whom surgical, radiotherapy, or chemotherapy intervention status was unknown or incorrectly listed (ie, total laryngectomy), and for whom the sequence of surgery and radiotherapy was unknown.
Potential treatment arms included chemotherapy, radiation, chemoradiation, or surgery followed by chemotherapy, radiation, or chemoradiotherapy. Definitive surgery was defined as any surgical intervention with intent to cure via craniofacial, endoscopic, or cranioendoscopic resection. This excluded all excisional and incisional biopsies. We, therefore, isolated only the patients who underwent surgical intervention with an attempt for negative margins.
| Outcomes
The main outcomes were (a) to identify variables that were predictive of a primary surgical treatment and (b) to compare staging systems between Kadish, traditional TNM, and Dulgeurov's modified-TNM with regard to their prognostic utility. Secondary outcomes included overall survival, margin status, as well as regional and distant metastases.
| Tumor characteristics
Tumors were staged according to the Kadish staging system, the "tumor" component of TNM staging as specified in the TNM Staging of Head and Neck Cancer and Neck Dissection Classification, fourth ed, 4, 10 and the modified TNM classification as proposed by Dulguerov et al. 5 A summary of this staging system can be seen in Table 1 . Other tumor-related characteristics included tumor grade and margin status. The grade was assessed according to the Hyams scale (I-IV).
Margin status was noted to be "positive" for the presence of macroscopically or microscopically positive margins. Covariates in this analysis included those which might conceptually affect margin status.
| Covariates
For all comparisons, P < 0.05 was considered to be statistically significant. Analyses were conducted using Stata Statistical software (Release 12.1; Stata Inc, College Station, TX).
3 | RESULTS
| Demographics, staging, and primary treatment modality
In the NCDB, we identified 1695 patients with the diagnosis of olfactory neuroblastoma, neurocytoma, or neuroepithelioma.
Of these, 1680 cases were histologically proven with biopsy and contained information allowing for proper staging. Additional patients were excluded who did not have complete treatment data, leaving 883 patients for analysis ( Figure 1 ). Approximately 59.9% of the patients were male, and 87.4% were white.
The median age was 54 years and demonstrated a unimodal distribution with a peak frequency in the sixth decade of life.
Grouping patients by the AJCC criteria for T-stage, a total of 21.9% of the 883 patients were found to be T1, 10.7% were T2, (Table 2) . 
| Factors associated with primary surgery
We analyzed factors associated with the use of primary surgical therapy using two different multivariable models, one that accounted for TNM staging and the other that accounted for Kadish staging. (Table 4) . Treatment modalities were too heterogeneous and with a small n to allow for effective comparisons.
Kaplan-Meier analysis and log-rank unadjusted, the pairwise comparison between Kadish stages demonstrated no significant differences in survival between Kadish A and B (P = 0.091) and
Kadish A and C (P = 0.36) (Figure 2 and Table 5 ). Using unadjusted comparisons between AJCC T-stages, there was no difference between T1 and T2, T1 and T3, as well as T3 and T4 tumors. ( Figure   3 and Table 5 ). Similarly, in Dulguerov T-stage there was no difference between T1 and T2 or T3 and T4 lesions ( Figure 4 and P < 0.0001). Within the AJCC staging system, there was no association between T-stages and survival (Table 5 ).
| Predictors of positive margins after surgery
In total, only 380 of the 511 patients undergoing surgery had margin status available for analysis. Of these 380 patients, 28. 
| DISCUSSION
ENB is an exceedingly rare tumor, making it very difficult to study.
Still, multiple institutions have published their own experience with the disease, analyzing data over extended periods of time to accumulate a larger sample size. [12] [13] [14] [15] [16] [17] Other studies have utilized existing literature for meta-analyses or even multi-institutional databases to obtain a larger sample size. The most important factor to consider when assessing any study of ENB is the duration of the study. Although our treatment timeline examined an additional two years of data compared with that of Konuthula et al, 6 it is not as robust compared to 30-year periods as can be seen in a SEER study. and nontumor factors that impact utilization of a primary surgical modality as well as the utility of the three commonly used staging systems in the modern era. Therefore, the 10-year horizon in this study is most appropriate for the questions assessed. In addition, recurrence typically occurs from 5 to 10 years postoperatively. 19 Ow et al 19 noted that 46% of their population experienced disease recurrence with a median time to recurrence of 6.9 years. Nevertheless, the NCDB provides other notable advantages to the SEER database including a larger sample size, an increased breadth of tumor characteristics, and more comprehensive treatment data.
A major pitfall of the NCDB is that only overall survival is recorded. Disease-free survival, disease-specific survival, and infor- Lastly, as with all large, database-driven studies, we depend upon information that has been entered by registrars who often must interpret operative reports and physician documentation. Errors in this process may affect the data and ultimately, conclusions that may be drawn from the data.
| CONCLUSION
This study represents the first analysis of multiple staging systems for ENB using the NCDB. The AJCC TNM, Dulguerov's modified TNM, and Kadish staging systems all poorly depict patient prognosis over a 10-year horizon. It is clear that longer-term studies are needed to assess the durability of these staging systems in the setting of this insidious pathology.
